Related Experiment Videos
Pharmaceutical and bacteriological study on povidone-iodine sugar ointment
T Shiraishi1, R Oka, Y Nakagawa
1Department of Pharmacy, Yamagata University Hospital, Japan.
Dermatology (Basel, Switzerland)
|January 1, 1997
Summary
A new, cost-effective povidone-iodine sugar ointment formulation demonstrates pharmaceutical stability comparable to commercial products. However, its effectiveness against methicillin-resistant Staphylococcus aureus (MRSA) requires further improvement for optimal clinical use.
Area of Science:
- Pharmaceutical Sciences
- Microbiology
- Dermatology
Background:
- Povidone-iodine sugar ointment is a valuable topical treatment for decubitus ulcers.
- Intrahospital formulations exist but commercial products are costly.
- A need exists for a stable, effective, and affordable povidone-iodine sugar ointment.
Purpose of the Study:
- To evaluate the efficacy of a novel, single-method povidone-iodine sugar ointment formulation.
- To compare its stability and antibacterial activity against a commercial product.
- To assess its potential as a low-cost alternative.
Main Methods:
- Pharmaceutical analysis (pH, iodine, sucrose) of formulations stored at 20°C and 40°C for 150 days.
- Bactericidal testing against standard strains and methicillin-resistant Staphylococcus aureus (MRSA).
- Comparison of three experimental formulas (P-1, P-2, P-3) with a commercial product (UP).
Main Results:
- Formulation P-3 exhibited pharmaceutical stability similar to UP after 150 days.
- Formulations P-1 and P-2 degraded significantly at 40°C within 60 days.
- Bactericidal activity against MRSA was not superior to other tested drugs for any formulation.
Conclusions:
- A stable, low-cost povidone-iodine sugar ointment formulation is achievable.
- Further research is needed to enhance the bactericidal efficacy against MRSA.
- The developed formulation shows promise but requires optimization for broader clinical application.